Does hepatic insulin resistance increase VLDL-triglyceride production and cause high triglycerides with low HDL cholesterol?

Pathophysiological mechanisms

Hepatic insulin resistance initiates a cascade of metabolic dysregulations characterized by a "selective" signaling defect in the liver. While the pathway regulating gluconeogenesis becomes resistant to insulin, the pathways governing lipogenesis remain highly active or are paradoxically stimulated:

• Selective insulin resistance: Under normal conditions, insulin suppresses the transcription factor FoxO1, which decreases the expression of microsomal triglyceride transfer protein (MTP) and apolipoprotein B-100 (apoB-100), thereby limiting very-low-density lipoprotein (VLDL) assembly. In insulin-resistant states, impaired FoxO1 suppression maintains elevated expression of MTP.
• Upregulated de novo lipogenesis: Concurrently, spared or hyperinsulinemia-driven activation of sterol regulatory element-binding protein 1c (SREBP-1c) and carbohydrate response element-binding protein (ChREBP) drives robust de novo lipogenesis. This provides an abundant pool of newly synthesized fatty acids to serve as the triglyceride core.
• Apolipoprotein stabilization: Insulin-resistant hepatocytes lose the normal post-translational degradation pathways for apoB-100. This stabilization, combined with high MTP and abundant triglycerides, maximizes VLDL assembly and systemic secretion.

Clinical evidence and lipid remodeling

The overproduction of large, triglyceride-rich VLDL (specifically VLDL1) particles directly alters the broader lipoprotein profile, leading to the classic atherogenic dyslipidemia triad (high triglycerides, low HDL, and small dense LDL):

• Elevated circulating triglycerides: Increased hepatic export of VLDL, combined with a reduction in lipoprotein lipase (LPL) activity (often secondary to elevated apolipoprotein C-III on insulin-resistant VLDL particles), leads to marked systemic hypertriglyceridemia.
• CETP-mediated lipid exchange: High circulating concentrations of VLDL-triglycerides drive the activity of cholesteryl ester transfer protein (CETP). CETP facilitates a reciprocal exchange, transferring triglycerides out of VLDL and into high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles in exchange for cholesteryl esters.
• Accelerated HDL clearance: The resulting triglyceride-enriched HDL particles become highly favorable substrates for hepatic lipase. Hepatic lipase rapidly hydrolyzes these triglycerides, shrinking the HDL particles. These small, dense, unstable HDL particles are rapidly cleared from circulation by the kidneys and liver, significantly reducing HDL cholesterol (HDL-C) levels.

Bottom line

Hepatic insulin resistance drives a dual defect of elevated SREBP-1c-mediated lipogenesis and unsuppressed FoxO1-MTP VLDL assembly, leading to VLDL-triglyceride overproduction. This excess VLDL fuels CETP-mediated lipid exchange, resulting in triglyceride-enriched HDL particles that undergo rapid, lipase-mediated clearance, directly causing the clinical phenotype of high triglycerides and low HDL cholesterol.